Celgosivir
As of the edition of 20 October 2026, Celgosivir is a small molecule: went quiet in 2013; acts on GAA, MGAM and MGAM2 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2013
- Kind
- Small molecule
- Registered trials
- 8, 0 stopped early
- Disease areas
- Infections; Digestive system; Immune system; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product8 company-target rows are on route A because of Celgosivir.
See the 8 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 7 | 6 | 0 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| BioWest Therapeutics | Lead sponsor of trials | 2004 to now |
| Sanofi | Lead sponsor of trials |